We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers were conspicuously absent on Tuesday from two drug pricing hearings on Capitol Hill, where lawmakers called out big pharma for setting high drug prices through manipulative means — and for refusing to show up to testify. Read More
Medicare and Medicaid beneficiaries received more insulin than they were prescribed, and the company billed the federal programs accordingly. Read More
A New York pharmacist group claims the misuse of “spread pricing” by the state’s pharmacy benefit managers has led to increased drug prices – especially for generics. Read More
PhRMA picked holes in a proposed Centers for Medicare & Medicaid Services rule increasing Medicare Advantage and Part D plans’ power to negotiate drug prices. Read More
FDA Commissioner Scott Gottlieb on Monday outlined the agency’s plans for promoting the use of real world evidence in clinical trials in 2019. Read More
The FDA has denied a citizen petition from Pfizer calling on the agency to use the company’s method for assessing sameness in generics for its estrogen drug Premarin (conjugated estrogens). Read More
UnitedHealthcare claims the companies conspired via telephone, text messages and emails as well as one-on-one meetings at trade association gatherings. Read More
The UK government released three pieces of draft legislation that cover the regulation of drugs, devices and clinical trials in a no-deal Brexit scenario. Read More
A federal court in New Jersey issued a restraining order on Friday temporarily blocking the release of a generic version of Indivior’s opioid dependence drug Suboxone (buprenorphine and naloxone) sublingual film. Read More